A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiujuan, Tang, Peng, Li, Shifei, Wang, Shushu, Liang, Yueyang, Zhong, Ling, Ren, Lin, Zhang, Ting, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827032/
https://www.ncbi.nlm.nih.gov/pubmed/29483583
http://dx.doi.org/10.1038/s41467-018-03210-2
_version_ 1783302417855545344
author Wu, Xiujuan
Tang, Peng
Li, Shifei
Wang, Shushu
Liang, Yueyang
Zhong, Ling
Ren, Lin
Zhang, Ting
Zhang, Yi
author_facet Wu, Xiujuan
Tang, Peng
Li, Shifei
Wang, Shushu
Liang, Yueyang
Zhong, Ling
Ren, Lin
Zhang, Ting
Zhang, Yi
author_sort Wu, Xiujuan
collection PubMed
description Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3–4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.
format Online
Article
Text
id pubmed-5827032
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58270322018-03-02 A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer Wu, Xiujuan Tang, Peng Li, Shifei Wang, Shushu Liang, Yueyang Zhong, Ling Ren, Lin Zhang, Ting Zhang, Yi Nat Commun Article Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3–4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects. Nature Publishing Group UK 2018-02-26 /pmc/articles/PMC5827032/ /pubmed/29483583 http://dx.doi.org/10.1038/s41467-018-03210-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wu, Xiujuan
Tang, Peng
Li, Shifei
Wang, Shushu
Liang, Yueyang
Zhong, Ling
Ren, Lin
Zhang, Ting
Zhang, Yi
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_full A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_fullStr A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_full_unstemmed A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_short A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
title_sort randomized and open-label phase ii trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827032/
https://www.ncbi.nlm.nih.gov/pubmed/29483583
http://dx.doi.org/10.1038/s41467-018-03210-2
work_keys_str_mv AT wuxiujuan arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT tangpeng arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT lishifei arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT wangshushu arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT liangyueyang arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT zhongling arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT renlin arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT zhangting arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT zhangyi arandomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT wuxiujuan randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT tangpeng randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT lishifei randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT wangshushu randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT liangyueyang randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT zhongling randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT renlin randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT zhangting randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer
AT zhangyi randomizedandopenlabelphaseiitrialreportstheefficacyofneoadjuvantlobaplatininbreastcancer

Ejemplares similares